Anticancer Therapies – Products

Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.

Metabolism is a key driver of CAR-T cell fitness and function. Hence, metabolic preconditioning methods can enhance the bioenergetic capacity of CAR-T cells in culture, supporting their persistence and antitumor activity

Predictive Oncology Inc. together with Cancer Research Horizons, announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.

SonALAsense has announced that the first cohort in Sonodynamic Therapy (SDT)-202 was fully enrolled.

Terumo Blood and Cell Technologies has announced US Food and Drug Administration clearance and official launch of its IMUGARD(R)WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days.

Akamis Bio has announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy to include a clinical collaboration with the Cancer Research Institute that will focus on advancing novel treatments for pancreatic cancer.

The platform will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.

Avacta Group plc announces that AVA6000 continues to show a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.

Sino Biological has developed a panel of quality proteins and antibodies for CD16 and accompanying molecules to support CAR-NK cell therapy research.

Personalis has announced a collaboration with UC San Francisco that will deploy a personalized liquid biopsy-based research use only assay for a study of patients with colorectal cancer.